BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 8881271)

  • 1. [Gene therapy for hereditary immunodeficiencies].
    Fischer A; de Saint-Basile G; Disanto JP; Hacein-Bey S; Sharara L; Cavazzana-Calvo M
    C R Seances Soc Biol Fil; 1996; 190(1):77-93. PubMed ID: 8881271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy of primary immunodeficiencies.
    Fischer A; De Saint Basile G; Disanto JP; Hacein-Bey S; Sharara L; Cavazzana-Calvo M
    Adv Nephrol Necker Hosp; 1997; 26():107-20. PubMed ID: 8922128
    [No Abstract]   [Full Text] [Related]  

  • 3. Gene therapy for inherited immunodeficiencies.
    Howe S; Thrasher AJ
    Curr Hematol Rep; 2003 Jul; 2(4):328-34. PubMed ID: 12901330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary immunodeficiencies: molecular aspects and treatment.
    Fischer A
    Bone Marrow Transplant; 1992; 9 Suppl 1():39-43. PubMed ID: 1354525
    [No Abstract]   [Full Text] [Related]  

  • 5. Gene therapy for primary adaptive immune deficiencies.
    Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
    J Allergy Clin Immunol; 2011 Jun; 127(6):1356-9. PubMed ID: 21624615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy of severe combined immunodeficiencies.
    Cavazzana-Calvo M; Hacein-Bey S; Yates F; de Villartay JP; Le Deist F; Fischer A
    J Gene Med; 2001; 3(3):201-6. PubMed ID: 11437325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy of severe combined immunodeficiencies.
    Fischer A; Hacein-Bey S; Cavazzana-Calvo M
    Nat Rev Immunol; 2002 Aug; 2(8):615-21. PubMed ID: 12154380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and prospects: gene therapy for inherited immunodeficiencies.
    Qasim W; Gaspar HB; Thrasher AJ
    Gene Ther; 2009 Nov; 16(11):1285-91. PubMed ID: 19776764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
    Hershfield MS
    Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe combined immunodeficiencies.
    Fischer A
    Immunodefic Rev; 1992; 3(2):83-100. PubMed ID: 1554500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
    Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
    Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
    Taupin P
    IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].
    Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M
    Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for primary immunodeficiencies.
    Thrasher AJ
    Immunol Allergy Clin North Am; 2008 May; 28(2):457-71, xi. PubMed ID: 18424342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe combined immunodeficiency. A model disease for molecular immunology and therapy.
    Fischer A; Le Deist F; Hacein-Bey-Abina S; André-Schmutz I; Basile Gde S; de Villartay JP; Cavazzana-Calvo M
    Immunol Rev; 2005 Feb; 203():98-109. PubMed ID: 15661024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for hematopoietic and immune disorders.
    Kohn DB
    Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S55-8. PubMed ID: 8971410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
    Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
    J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on gene therapy of inherited immune deficiencies.
    Engel BC; Kohn DB; Podsakoff GM
    Curr Opin Mol Ther; 2003 Oct; 5(5):503-7. PubMed ID: 14601519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular defects in T- and B-cell primary immunodeficiency diseases.
    Cunningham-Rundles C; Ponda PP
    Nat Rev Immunol; 2005 Nov; 5(11):880-92. PubMed ID: 16261175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.